55954-27-3

Basic information

• Product Name: Benzeneacetamide,2,4-dichloro-
• Synonyms: 2,4-Dichlorophenylacetamide;2-(2,4-Dichlorophenyl)acetamide
• CAS NO: 55954-27-3
• Molecular Formula: C8H7 Cl2 N O
• Molecular Weight: 204.056
• Mol File: 55954-27-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzeneacetamide,2,4-dichloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetamide,2,4-dichloro-(55954-27-3)
• EPA Substance Registry System: Benzeneacetamide,2,4-dichloro-(55954-27-3)

Safety Data

• Hazardous Substances Data: 55954-27-3(Hazardous Substances Data)

Upstream product

• 2234-16-4 1-(2,4-dichlorophenyl)ethan-1-one 
• 19719-28-9 2,4-dichlorophenylacetic acid 
• 53056-20-5 2,4-dichlorophenylacetyl chloride 

Downstream Products

• 1265131-70-1 3-(2,4-dichlorophenyl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione 
• 883946-62-1 2-(2,4-dichlorophenyl)ethanethioamide 
• 280744-09-4 SB-216763 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Development of [18F]Maleimide-Based Glycogen Synthase Kinase-3β Ligands for Positron Emission Tomography Imaging

Dysregulation of glycogen synthase kinase-3β (GSK-3β) is implicated in the pathogenesis of neurodegenerative and psychiatric disorders. Thus, development of GSK-3β radiotracers for positron emission tomography (PET) imaging is of paramount importance, because such a noninvasive imaging technique would allow better understanding of the link between the activity of GSK-3β and central nervous system disorders in living organisms, and it would enable early detection of the enzyme’s aberrant activity. Herein, we report the synthesis and biological evaluation of a series of fluorine-substituted maleimide derivatives that are high-affinity GSK-3β inhibitors. Radiosynthesis of a potential GSK-3β tracer [18F]10a is achieved. Preliminary in vivo PET imaging studies in rodents show moderate brain uptake, although no saturable binding was observed in the brain. Further refinement of the lead scaffold to develop potent [18F]-labeled GSK-3 radiotracers for PET imaging of the central nervous system is warranted.

DRUG FOR NERVE REGENERATION

An object of the present invention is to provide a nerve regenerating drug, an agent for the promotion of neuropoiesis of a neural stem cell, a neuron obtained by culturing a neural stem cell in the presence of the agent for the promotion of neuropoiesis,